Open AccessOleic Acid Ameliorates Amyloidosis in Cellular and Mouse Models of Alzheimer's Disease
Author(s) -
Amtul Zareen,
Westaway David,
Cechetto David F.,
Rozmahel Richard F.
Publication year - 2011
Publication title -
brain pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.986
H-Index - 132
eISSN - 1750-3639
pISSN - 1015-6305
DOI - 10.1111/j.1750-3639.2010.00449.x
Subject(s) - genetically modified mouse , insulin degrading enzyme , amyloid precursor protein , presenilin , endocrinology , transgene , medicine , alzheimer's disease , neuropathology , oleic acid , chemistry , amyloid (mycology) , amyloid beta , biochemistry , insulin , biology , disease , gene , inorganic chemistry
Several lines of evidence support protective as well as deleterious effects of oleic acid (OA) on Alzheimer's disease (AD) and other neurological disorders; however, the bases of these effects are unclear. Our investigation demonstrates that amyloid precursor protein (APP) 695 transfected Cos‐7 cells supplemented with OA have reduced secreted amyloid‐beta (Aβ) levels. An early‐onset AD transgenic mouse model expressing the double‐mutant form of human APP, Swedish (K670N/M671L) and Indiana (V717F), corroborated our in vitro findings when they were fed a high‐protein, low‐fat (18% reduction), cholesterol‐free diet enriched with OA. These mice exhibited an increase in Aβ40/Aβ42 ratio, reduced levels of beta‐site APP cleaving enzyme (BACE) and reduced presenilin levels along with reduced amyloid plaques in the brain. The decrease in BACE levels was accompanied by increased levels of a non‐amyloidogenic soluble form of APP (sAPPα). Furthermore, the low‐fat/+OA diet resulted in an augmentation of insulin‐degrading enzyme and insulin‐like growth factor‐II. These results suggest that OA supplementation and cholesterol intake restriction in a mouse model of AD reduce AD‐type neuropathology.